Skip to main content
Top
Published in: Hepatology International 1/2008

01-03-2008 | Original Article

Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma

Authors: Koichi Obara, Nobuyuki Matsumoto, Masaru Okamoto, Minoru Kobayashi, Hiroki Ikeda, Hideaki Takahashi, Yoshiki Katakura, Kotaro Matsunaga, Toshiya Ishii, Chiaki Okuse, Michihiro Suzuki, Fumio Itoh

Published in: Hepatology International | Issue 1/2008

Login to get access

Abstract

Background

Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a thermoablative technique to kill tumor tissue by generating areas of coagulative necrosis. Recent reports have raised concern that RFA may lead to a local recurrence of HCC with an aggressive phenotype and unfavorable prognosis, suggesting that RFA may induce further malignant transformation of HCC. However, the biological effects of RFA on HCC cells have not been directly analyzed. The aim of this study was to determine whether heat stress of the type associated with RFA induces malignant transformation of HCC.

Methods

We assessed the sensitivity of three HCC cell lines (HepG2, Alexander, and Huh7) to heat treatment for 10 min. We then determined the temperature at which a heat-resistant subline can be generated. We established and expanded sublines that survived heat treatment. And their proliferation rates, heat sensitivities, and invasive capacities were further examined.

Results

All HepG2 died after 48°C treatment, whereas 49°C treatment was required to kill all Alexander and HuH7. We generated 20 sublines for each parental cell line. A HepG2 subline, HepG2#18, proliferated 100% faster than parental HepG2. Moreover, HepG2#18 survived after 50°C treatment, whereas all parental HepG2 died after heat treatments at 48°C or higher.

Conclusion

Our results showed that even a single heat treatment could induce further transformation of an HCC cell line. Our results suggest that an insufficient treatment of HCC by RFA that enables survival of some cells might induce further malignant transformation in vivo.
Literature
1.
go back to reference Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609–19.PubMedCrossRef Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609–19.PubMedCrossRef
2.
go back to reference Buscarini L, Buscarini E. Therapy of HCC-radiofrequency ablation. Hepatogastroenterology 2001;48:15–9.PubMed Buscarini L, Buscarini E. Therapy of HCC-radiofrequency ablation. Hepatogastroenterology 2001;48:15–9.PubMed
3.
go back to reference Livraghi T, Lazzaroni S, Meloni F. Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound 2001;13:159–66.PubMedCrossRef Livraghi T, Lazzaroni S, Meloni F. Radiofrequency thermal ablation of hepatocellular carcinoma. Eur J Ultrasound 2001;13:159–66.PubMedCrossRef
4.
go back to reference Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535–47.PubMedCrossRef Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535–47.PubMedCrossRef
6.
go back to reference Scudamore CH, Lee SI, Patterson EJ, Buczkowski AK, July LV, Chung SW, et al. Radiofrequency ablation followed by resection of malignant liver tumors. Am J Surg 1999;177:411–7.PubMedCrossRef Scudamore CH, Lee SI, Patterson EJ, Buczkowski AK, July LV, Chung SW, et al. Radiofrequency ablation followed by resection of malignant liver tumors. Am J Surg 1999;177:411–7.PubMedCrossRef
7.
go back to reference Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88:2452–63.PubMedCrossRef Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88:2452–63.PubMedCrossRef
8.
go back to reference Itoh T, Orba Y, Takei H, Ishida Y, Saitoh M, Nakamura H, et al. Immunohistochemical detection of hepatocellular carcinoma in the setting of ongoing necrosis after radiofrequency ablation. Mod Pathol 2002;15:110–5.PubMedCrossRef Itoh T, Orba Y, Takei H, Ishida Y, Saitoh M, Nakamura H, et al. Immunohistochemical detection of hepatocellular carcinoma in the setting of ongoing necrosis after radiofrequency ablation. Mod Pathol 2002;15:110–5.PubMedCrossRef
9.
go back to reference Morimoto M, Sugimori K, Shirato K, Kokawa A, Tomita N, Saito T, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology 2002;35:1467–75.PubMedCrossRef Morimoto M, Sugimori K, Shirato K, Kokawa A, Tomita N, Saito T, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology 2002;35:1467–75.PubMedCrossRef
10.
go back to reference Nicoli N, Casaril A, Marchiori L, Mangiante G, Hasheminia AR. Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. J Hepatobiliary Pancreat Surg 2001;8:417–21.PubMedCrossRef Nicoli N, Casaril A, Marchiori L, Mangiante G, Hasheminia AR. Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. J Hepatobiliary Pancreat Surg 2001;8:417–21.PubMedCrossRef
11.
go back to reference Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001;13:291–4.PubMedCrossRef Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001;13:291–4.PubMedCrossRef
12.
go back to reference Koda M, Maeda Y, Matsunaga Y, Mimura K, Murawaki Y, Horie Y. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 2003;27:163–7.PubMedCrossRef Koda M, Maeda Y, Matsunaga Y, Mimura K, Murawaki Y, Horie Y. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 2003;27:163–7.PubMedCrossRef
13.
go back to reference Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003;50:2179–84.PubMed Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003;50:2179–84.PubMed
14.
go back to reference Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003;8:332–5.PubMedCrossRef Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003;8:332–5.PubMedCrossRef
15.
go back to reference Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, et al. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol 2004;10:1137–40.PubMed Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, et al. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol 2004;10:1137–40.PubMed
16.
go back to reference Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol 1989;23(Suppl):S4–8.PubMedCrossRef Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol 1989;23(Suppl):S4–8.PubMedCrossRef
17.
go back to reference van Rijn J, van den Berg J, Schamhart DH, van Wijk R. Morphological response and survival of hepatoma cells during fractionated hyperthermia: effect of glycerol. Radiat Res 1984;98:471–8.PubMedCrossRef van Rijn J, van den Berg J, Schamhart DH, van Wijk R. Morphological response and survival of hepatoma cells during fractionated hyperthermia: effect of glycerol. Radiat Res 1984;98:471–8.PubMedCrossRef
18.
go back to reference Schamhart DH, van Walraven HS, Wiegant FA, Linnemans WA, van Rijn J, van den Berg J, et al. Thermotolerance in cultured hepatoma cells: cell viability, cell morphology, protein synthesis, and heat-shock proteins. Radiat Res 1984;98:82–95.PubMedCrossRef Schamhart DH, van Walraven HS, Wiegant FA, Linnemans WA, van Rijn J, van den Berg J, et al. Thermotolerance in cultured hepatoma cells: cell viability, cell morphology, protein synthesis, and heat-shock proteins. Radiat Res 1984;98:82–95.PubMedCrossRef
19.
go back to reference Wiegant FA, van Bergen en Henegouwen PM, van Dongen G, Linnemans WA. Stress-induced thermotolerance of the cytoskeleton of mouse neuroblastoma N2A cells and rat Reuber H35 hepatoma cells. Cancer Res 1987;47:1674–80.PubMed Wiegant FA, van Bergen en Henegouwen PM, van Dongen G, Linnemans WA. Stress-induced thermotolerance of the cytoskeleton of mouse neuroblastoma N2A cells and rat Reuber H35 hepatoma cells. Cancer Res 1987;47:1674–80.PubMed
20.
go back to reference Coad JE, Kosari K, Humar A, Sielaff TD. Radiofrequency ablation causes ‘thermal fixation’ of hepatocellular carcinoma: a post-liver transplant histopathologic study. Clin Transplant 2003;17:377–84.PubMedCrossRef Coad JE, Kosari K, Humar A, Sielaff TD. Radiofrequency ablation causes ‘thermal fixation’ of hepatocellular carcinoma: a post-liver transplant histopathologic study. Clin Transplant 2003;17:377–84.PubMedCrossRef
21.
go back to reference Mertyna P, Hines-Peralta A, Liu ZJ, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: variability in heat sensitivity in tumors and tissues. J Vasc Interv Radiol 2007;18:647–54.PubMedCrossRef Mertyna P, Hines-Peralta A, Liu ZJ, Halpern E, Goldberg W, Goldberg SN. Radiofrequency ablation: variability in heat sensitivity in tumors and tissues. J Vasc Interv Radiol 2007;18:647–54.PubMedCrossRef
22.
go back to reference Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497–9.PubMedCrossRef Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980;209:497–9.PubMedCrossRef
23.
go back to reference Alexander JJ, Bey EM, Geddes EW, Lecatsas G. Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J 1976;50:2124–8.PubMed Alexander JJ, Bey EM, Geddes EW, Lecatsas G. Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J 1976;50:2124–8.PubMed
24.
go back to reference Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858–63.PubMed Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858–63.PubMed
25.
go back to reference Van Rijn J, Van den Berg J, Souren JE, Van Wijk R, Joenje H. Hepatoma cells adapted to proliferate under normally lethal hyperthermic stress conditions show rapid decay of thermoresistance and heat shock protein synthesis when returned to 37 degrees C. Int J Hyperthermia 1995;11:697–708.PubMedCrossRef Van Rijn J, Van den Berg J, Souren JE, Van Wijk R, Joenje H. Hepatoma cells adapted to proliferate under normally lethal hyperthermic stress conditions show rapid decay of thermoresistance and heat shock protein synthesis when returned to 37 degrees C. Int J Hyperthermia 1995;11:697–708.PubMedCrossRef
26.
go back to reference Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Barcelona Clinical Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352–60.PubMedCrossRef Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Barcelona Clinical Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352–60.PubMedCrossRef
27.
go back to reference Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007;13:1003–9.PubMed Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007;13:1003–9.PubMed
Metadata
Title
Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma
Authors
Koichi Obara
Nobuyuki Matsumoto
Masaru Okamoto
Minoru Kobayashi
Hiroki Ikeda
Hideaki Takahashi
Yoshiki Katakura
Kotaro Matsunaga
Toshiya Ishii
Chiaki Okuse
Michihiro Suzuki
Fumio Itoh
Publication date
01-03-2008
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 1/2008
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-007-9040-3

Other articles of this Issue 1/2008

Hepatology International 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.